Eurofins Scientific Management

Management Kriterienprüfungen 3/4

Wir verfügen derzeit nicht über ausreichende Informationen über den CEO.

Wichtige Informationen

Gilles Martin

Geschäftsführender

€1.4m

Gesamtvergütung

Prozentsatz des Geschäftsführergehalts	97.6%
Amtszeit als Geschäftsführer	36.8yrs
Eigentum des Geschäftsführers	0.00001%
Durchschnittliche Amtszeit des Managements	keine Daten
Durchschnittliche Amtszeit der Vorstandsmitglieder	9.1yrs

Jüngste Management Updates

Recent updates

Analyse der Geschäftsführervergütung

Wie hat sich die Vergütung von Gilles Martin im Vergleich zu den Einnahmen von Eurofins Scientific verändert?
Datum	Gesamtvergütung	Gehalt	Unternehmensgewinne
Jun 30 2024	n/a	n/a	€326m
Mar 31 2024	n/a	n/a	€291m
Dec 31 2023	€1m	€1m	€257m
Sep 30 2023	n/a	n/a	€335m
Jun 30 2023	n/a	n/a	€414m
Mar 31 2023	n/a	n/a	€497m
Dec 31 2022	€1m	€1m	€581m
Sep 30 2022	n/a	n/a	€612m
Jun 30 2022	n/a	n/a	€643m
Mar 31 2022	n/a	n/a	€696m
Dec 31 2021	€1m	€1m	€749m
Sep 30 2021	n/a	n/a	€786m
Jun 30 2021	n/a	n/a	€824m
Mar 31 2021	n/a	n/a	€665m
Dec 31 2020	€1m	€1m	€505m
Sep 30 2020	n/a	n/a	€347m
Jun 30 2020	n/a	n/a	€190m
Mar 31 2020	n/a	n/a	€168m
Dec 31 2019	€1m	€1m	€146m
Sep 30 2019	n/a	n/a	€144m
Jun 30 2019	n/a	n/a	€143m
Mar 31 2019	n/a	n/a	€159m
Dec 31 2018	€1m	€1m	€175m

Vergütung im Vergleich zum Markt: GillesDie Gesamtvergütung ($USD1.43M) liegt unter dem Durchschnitt von Unternehmen ähnlicher Größe auf dem Markt Austrian ($USD2.50M).

Entschädigung vs. Einkommen: GillesDie Vergütung des Vorstandsvorsitzenden entsprach im vergangenen Jahr der Unternehmensleistung.

Geschäftsführer

Gilles Martin (61 yo)

36.8yrs

Amtszeit

€1,351,000

Vergütung

Dr. Gilles G. Martin, Ph D., serves as the Chief Executive Officer at Eurofins Scientific, Inc. Dr. Martin serves as Chief Executive Officer of Eurofins Nihon Kankyo K.K. and Eurofins Scientific Group. He...

Vorstandsmitglieder

Name	Position	Amtszeit	Vergütung	Eigentümerschaft
Gilles Martin	Chairman of the Board & CEO	36.8yrs	€1.35m	0.000010% € 889.2
Valerie Hanote	Executive Director	34.8yrs	€400.69k	0.000010% € 889.2
Yves-Loïc Martin	Non-Executive Director	32.8yrs	€33.00k	0.077% € 6.8m
Patrizia Luchetta	Independent Non-Executive Director	7.6yrs	€71.50k	keine Daten
Ivo Rauh	Independent Non-Executive Director	3.6yrs	€55.00k	keine Daten
Fereshteh Pouchantchi	Independent Non-Executive Director	10.6yrs	€44.00k	0.0033% € 296.1k
Evie Roos	Independent Non-Executive Director	3.6yrs	€66.00k	0.00032% € 28.5k
Pascal Rakovsky	Lead Independent Non-Executive Director	4.4yrs	€93.50k	keine Daten
Erica Monfardini	Independent Non-Executive Director	no data	keine Daten	keine Daten

9.1yrs

Durchschnittliche Betriebszugehörigkeit

60.5yo

Durchschnittliches Alter

Erfahrener Vorstand: ESFDie Vorstandsmitglieder gelten als erfahren (9.1 Jahre durchschnittliche Amtszeit).

Eurofins Scientific Management

Management Kriterienprüfungen 3/4

Wichtige Informationen

Jüngste Management Updates

Insufficient new directors

Eurofins Scientific SE, Annual General Meeting, Apr 25, 2024

Recent updates

Eurofins Scientific SE to Report First Half, 2025 Results on Jul 24, 2025

Eurofins Scientific SE to Report Fiscal Year 2024 Results on Feb 26, 2025

Eurofins Scientific SE (ENXTPA:ERF) agreed to acquire clinical diagnostics operations in Spain from SYNLAB AG (HMSE:SYAB).

Investor sentiment deteriorates as stock falls 15%

Eurofins Scientific SE (ENXTPA:ERF) acquired Infinity Laboratories, LLC from Imperial Capital Acquisition Fund VI and Imperial Capital Limited.

First half 2024 earnings released: EPS: €1.15 (vs €0.65 in 1H 2023)

Eurofins Scientific SE Provides Earnings Guidance for the Fiscal Year 2024

Dividend of €0.50 announced

Insufficient new directors

Eurofins Scientific SE (ENXTPA:ERF) acquired Ascend Clinical, LLC.

Eurofins Scientific SE, Annual General Meeting, Apr 25, 2024

New minor risk - Earnings quality

Full year 2023 earnings released: EPS: €1.61 (vs €3.02 in FY 2022)

New minor risk - Profit margin trend

First half 2023 earnings released: EPS: €0.79 (vs €1.52 in 1H 2022)

Eurofins Scientific SE Updates Revenue Guidance for Fiscal Year 2023 and year 2027

Upcoming dividend of €1.00 per share at 1.8% yield

Now 22% undervalued after recent price drop

Eurofins Scientific SE to Report First Half, 2023 Results on Jul 26, 2023

Now 21% undervalued after recent price drop

Now 21% undervalued after recent price drop

Full year 2022 earnings released: EPS: €3.16 (vs €3.91 in FY 2021)

Now 20% undervalued after recent price drop

Eurofins Scientific SE to Report Fiscal Year 2022 Results on Feb 21, 2023

Eurofins Scientific SE to Report Q3, 2022 Results on Oct 18, 2022

Now 22% undervalued after recent price drop

Eurofins Scientific SE (ENXTPA:ERF) signed of an agreement to acquire unknown majority stake in QSAI Analysis and Research Center Co., Ltd.

Eurofins Scientific SE (ENXTPA:ERF) acquired Wessling Hungary Kornyezetvedelmi, Elelmiszerbiztonsagi, Egeszsegvedelmi Es Minosegugyi Sz.

First half 2022 earnings released: EPS: €1.62 (vs €2.09 in 1H 2021)

Eurofins Scientific SE Revised Earnings Guidance for the Fiscal 2022

Upcoming dividend of €1.00 per share

Eurofins Scientific SE (ENXTPA:ERF) agreed to acquire unknown majority stake in Ajal for Laboratories from Saudi Ajal Laboratories.

Eurofins Scientific SE (ENXTPA:ERF) acquires an unknown majority stake in Repertoire Genesis Inc.

Health Canada Approves Eurofins CDMO Alphora Inc.’s Standard Processing License for Synthetic Phytocannabinoids

Eurofins Scientific SE Provides Earnings Guidance for the Fiscal Year 2023 and 2024

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

Eurofins Scientific SE to Report Q1, 2022 Results on Apr 21, 2022

Eurofins’ empowerDX Launches PFAS Exposure™ in the U.S, the First at-Home Blood Test to Detect and Measure 40+ PFAS Compounds

Eurofins Technologies Launches New Lateral Flow Reader Rapidscan ST5-W as Single Platform Validated for Multiple Food and Environmental Rapid Tests

Eurofins Scientific SE (ENXTPA:ERF) entered into a share purchase agreement to acquire GeneticLab Co., Ltd. from Trans Genic Inc. (TSE:2342).

Eurofins Technologies Launches New Multiplex RT-PCR Respiratory Panel for SARS-CoV-2, Flu A, Flu B, RSV A and RSV B

First half 2021 earnings released: EPS €2.17 (vs €0.43 in 1H 2020)

Eurofins Scientific SE (ENXTPA:ERF) acquired bioskin GmbH.

Eurofins Launches a New Multiplex PCR Assay for Rapid Detection of the B.1.617 India Sars-Cov-2 Variant

Eurofins Scientific Adds Virus Variant Detection to its SARS-CoV-2 Monitoring Solution for Wastewater, Surface, Air and Worn Masks

Full year 2020 earnings released: EPS €2.71 (vs €0.82 in FY 2019)

Revenue beats expectations

Eurofins Environment Testing America Expands Reporting to 75 Compounds

Eurofins Scientific SE to Report Fiscal Year 2020 Results on Mar 01, 2021

Eurofins Scientific SE (ENXTPA:ERF) agreed to acquire Beacon Discovery, Inc.

Eurofins Adds Virus Variant Distinction to its Sars-Cov-2 Monitoring Solution for Wastewater, Food and Environmental Surfaces

Eurofins Launches New Ultra-Fast Extraction-Free RT-PCR Method and Upgrades its RT-PCR Assay for Use with Pharynx Gargle and Saliva Sample Matrices

New 90-day high: €80.51

New 90-day high: €73.16

Eurofins Genomics Launches Cost-Effective SARS-CoV-2 Full-Length Viral Genome Sequencing Services Essential in the Identification of Viral Mutations

Eurofins U.S. Clinical Diagnostic Laboratories At-Home COVID-19 Test Now Being Offered in All 50 States

Eurofins Technologies Launches New and Improved Lateral Flow Device Product Line for Allergen Detection in Foodstuffs and Environmental Samples

Eurofins Scientific SE (ENXTPA:ERF) acquired Taiyo Techno Research.

Eurofins Launches Sensitive, Fast and Cost-effective High Throughput SARS-CoV-2 Test Kits for Widely Available Sanger Sequencing Equipment

Eurofins U.S. Clinical Diagnostics Network Receives EUA Approval of At Home COVID-19 Test

Eurofins Scientific Se Launches Europe’S First Validated Test Method to Evaluate Filtration Capacity of Masks for Sars-Cov-2